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ABSTRACT
Pharmaceutically valuable products from microalgae and its industrial commercialization today is still in its infancy and can be seen as a gateway 
to a multibillion dollar industry. Microalgae generally grow autotrophically and are ubiquitous in nature. They represent a major untapped resource 
of genetic potential for valuable bioactive agents and fine biochemical. This proven ability of microalgae to produce these compounds places these 
microorganisms in the biotechnological spotlight for applications and commercialization as in the pharmaceutical industry. The production of 
microalgal metabolites, which stimulate defense mechanisms in the human body, has spurred intense study of the application of microalgal biomass 
and products thereof in various food preparations, pharmacological and medical products. There is, therefore, a huge scope for further study of the 
identified algal compounds and their activities in the treatment and prevention of various diseases, in addition to an ongoing search for other, as yet 
undetected, metabolites.
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INTRODUCTION
The markets for both pharmaceuticals and nutraceuticals are growing 
quickly worldwide, and it is this global scope that particularly attracts 
consumers. A growing proportion of today’s promising pharmaceutical 
research focuses on the production of potent bioactive compounds 
from algae. Thus, the untapped potential of algae in the field of 
pharmaceuticals has to be still explored to grow and capitalize on 
tremendous global marketing opportunities.
Algae are emerging as one of the most promising sources of sustainable 
crops with potential health benefits including protein, Omega 3, and 
antioxidants. The pharmaceutical potential of the large variety of algae 
species is just starting to be explored. A lot of research aims to enhance 
particular pigments and products within certain algae species that have 
nutritional, nutraceutical, or pharmaceutical value.
While the pharmaceutical content in the common baseline algae strains 
is small, current market values for these products are extremely high. The 
major products currently being commercialized or under consideration 
for commercial extraction include carotenoids, phycobilins, fatty acids, 
polysaccharides, vitamins, sterols, and biologically active molecules for 
use in human and animal health. There is a range of pharmaceutical 
products derived from algae. Some of them include: Antimicrobials, 
antivirals and antifungals, neuroprotective products, therapeutic 
proteins, and drugs.
WHAT ARE BIOACTIVE COMPOUNDS?
Bioactive compounds are physiologically active substances with 
functional properties in the human body. There is, therefore, great 
enthusiasm for the development and manufacture of various 
biocompounds that can potentially be used as functional ingredients 
such as carotenoids, phycocyanins (PC), polyphenols, fatty acids, 
and polyunsaturated compounds [1]. An interest in the production 
of bioactive compounds from natural sources has recently emerged, 
driven by a growing number of scientific studies that demonstrate the 
beneficial effects of these compounds on health benefits [2]. These 
natural products are important in the search for new pharmacologically 
active compounds and play an important role in new drug discovery 
for the treatment of human diseases [3]. Many clinically viable and 
commercially available drugs with antitumor and anti-infective activity 
originated as natural products.
MICROALGAE AS A SOURCE OF BIOACTIVE COMPOUNDS
Algae, in general, are found all over the globe and in every ecological 
niche conceivable. They, therefore, have unique properties to help them 
survive even in adverse conditions they encounter in the ecosystem. 
These unique attributes are brought about by changes in their 
macro- and micro-molecular constituents in the cell which are formed 
under the stressed situations the algae faces. These unique metabolites 
often have special properties and can be considered as bioactive 
compounds in addition to the macromolecules the algae generally have. 
There are thousands and thousands of algal species and only 25-30% 
of them have been identified and collected. Hence, there is a huge 
unexplored resource available to be exploited in the pharmaceutical 
industry. Microalgae are known to produce various therapeutically 
effective biocompounds that can be obtained from the biomass or 
released extracellularly into the medium [4]. These microorganisms 
contain many bioactive compounds such as proteins, polysaccharides, 
lipids, vitamins, enzymes, sterols, and other high-value compounds 
with pharmaceutical and nutritional importance that can be employed 
for commercial use [5].
TYPES OF BIOACTIVE COMPOUNDS
Bioactive compounds from microalgae can be obtained directly from 
primary metabolisms, such as proteins, fatty acids, vitamins, and 
pigments, or can be synthesized from secondary metabolism. Such 
compounds can present antifungal, antiviral, antialgal, antienzymatic, 
or antibiotic actions [6]. Many of these compounds (cyanovirin, oleic 
acid, linolenic acid, palmitoleic acid, vitamin E, B12, β-carotene, PC, 
lutein, and zeaxanthin) have antimicrobial, antioxidant, and anti-
inflammatory properties, with the potential for the reduction and 
prevention of diseases [7-10]. In most microalgae, the bioactive 
compounds are accumulated in the biomass; however, in some cases, 
these metabolites are excreted into the medium; these are known as 
exometabolites.
RESEARCH RESULTS ON WELL-STUDIED ALGAL STRAINS
A huge volume of research on bioactive compounds from well-studied 
algal forms such as Arthrospira (Spirulina), Botryococcus braunii, 
Chlorella vulgaris, Dunaliella salina, Haematococcus pluvialis, and Nostoc 
has led to the identification of antimicrobial, antiviral, anticoagulant 
antienzymatic, antioxidant, antifungal, anti-inflammatory, and 
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anticancer activity [1,5,11,12,14]. These studies have been based on the 
extraction of bioactive compounds from these microalgae [15-17]. The 
prokaryotic blue-green algae or cyanobacteria are known to produce 
intracellular and extracellular metabolites with potential biological 
activities, such as antibacterial, antifungal, antiviral, antitumor, anti-
human immunodeficiency virus (HIV), anti-inflammatory, antioxidant, 
antimalarial, herbicidal, and immunosuppressant effects [18,19]. The 
therapeutic importance of Spirulina, one of the most extensively studied 
blue-green algae, has been reported in several studies. These include its 
use in the treatment of hyperlipidemia, cancer, HIV, diabetes, obesity, 
and hypertension, the improvement of the immune response in renal 
protection against heavy metals and drugs, and the reduction in serum 
levels of glucose and lipids, among others [20-23].
Nostoc, another blue-green alga, biomass has been used in the medical 
field and as a dietary supplement because of its protein, vitamin, and 
fatty acid content. The medical value of this microalga was established 
by its use in the treatment of fistula and for some forms of cancer [24]. 
Historically, the biomass of Nostoc is described as anti-inflammatory, 
and it is also found to aid in digestion, blood pressure control, and 
immune boosting. Cyanovirin, a potential protein molecule produced 
by a Nostoc species, showed a positive effect in the treatment of HIV 
and influenza A (H1N1) [25,7]. Nostoc species also contains a spectrum 
of polyunsaturated fatty acids (PUFAs) that include essential fatty 
acids such as linoleic, α-linolenic, γ-linolenic, octadecatetraenoic, and 
eicosapentaenoic acid [26]. Essential fatty acids are precursors of 
prostaglandins, attracting significant interest from the pharmaceutical 
industry.
Several other studies suggest that Nostoc produces compounds with 
antimicrobial, antiviral, and anticancer activity. These results have 
encouraged its cultivation on a large scale, and it has great economic 
potential due to its nutritional and pharmaceutical importance and the 
pharmaceutical industry [27].
Chlorella, a very common green alga was discovered by the Japanese, 
traditional consumers of algae, who usually eat and enjoy it as a food 
supplement. Chlorella is rich in chlorophyll, proteins, polysaccharides, 
vitamins, minerals, and essential amino acids with molecular 
constituents of 53% (w/w) protein, 23% (w/w) carbohydrate, 9% 
(w/w) lipids, and 5% (w/w) minerals and oligo elements [28]. These 
nutrient concentrations can be varied by manipulation of the culture 
conditions, in which they are grown. The biomass of Chlorella is also rich 
in vitamin B complex, especially B12, which are vital in the formation 
and regeneration of blood cells. Like Spirulina, Chlorella has a GRAS 
certificate issued by the FDA and can thus be used as food without risk 
to human health when grown in a suitable environment with proper 
hygiene and good manufacturing practices [28,29].
The pharmaceutical importance of Chlorella is attributed to its medicinal 
properties. There is ample experimental evidence of its antitumor, 
anticoagulant, antibacterial, antioxidant, and antihyperlipidemia effects 
in addition to a hepatoprotective property and the immune-stimulatory 
activity of enzymatic protein hydrolyzate [30-34]. Many antioxidant 
compounds are thought to be responsible for Chlorella functional 
activities. Antioxidants such as lutein, α-carotene, β-carotene, ascorbic 
acid, and α-tocopherol, which are active against free radicals, have been 
identified. Some of these compounds not only are important as natural 
colorants or additives but also may be useful in reducing the incidence 
of cancer and in the prevention of macular degeneration [30,35].
By far one of the most important bioactive compounds in Chlorella is 
β-1,3 glucan, an active immune stimulator that reduces free radicals 
and blood cholesterol. The efficacy of this compound against gastric 
ulcers, sores, and constipation has been reported. It also has been 
demonstrated to have preventive action against atherosclerosis and 
hypercholesterolemia, as well as antitumor activity [36]. Chlorella is 
produced by more than 70 companies. Taiwan Chlorella Manufacturing 
Co. (Taipei, Taiwan) is the world’s largest producer of Chlorella, with 
over 400,000 tons of biomass produced per year. The significant 
production also occurs in Klötze (Germany) (80–100 t year−1 of dry 
biomass) [37].
Dunaliella is also a green unicellular halotolerant microalga that has 
been extensively studied for its pharmaceutically active compounds. 
This microalga is popularly studied as an extremophile, unique 
physiology, and therefore, many biotechnological applications. 
Dunaliella is a source of carotenoids, glycerol, lipids, and other bioactive 
compounds such as enzymes and vitamins. This microalga is a major 
source of natural β-carotene, able to produce up to 14% of its dry 
weight under conditions of high salinity, light, and temperature as well 
as nutrient limitation [38]. In addition to β-carotene, this microalga is 
rich in protein and essential fatty acids, which can be consumed safely, 
as evidenced by GRAS recognition [28]. Compounds in the Dunaliella 
biomass have various biological activities such as antioxidant, 
antihypertensive, bronchodilatory, analgesic, muscle relaxant, 
hepatoprotective, and antiedemal properties. The microalgal biomass 
can also be used directly in food and pharmaceutical formulations [39].
Chang et al. [40] showed that Dunaliella cells contained antibiotic 
substances. According to these authors, the crude extract of this 
microalga strongly inhibited the growth of Staphylococcus aureus, 
Bacillus cereus, Bacillus subtilis, and Enterobacter aerogenes. In 
another study, Dunaliella showed antibacterial activity against other 
microorganisms of importance to the food industry, which includes 
Escherichia coli, Candida albicans, and Aspergillus niger [41,42]. Under 
ideal growing conditions, Dunaliella can be stimulated to produce 
approximately 400 mg of β-carotene per square meter of growing area.
The cultivation of Dunaliellafor, the production of β-carotene, has been 
conducted in several countries, including Australia, India, Israel, the 
USA, and China [43-45]. An ingredient of Dunaliella with a strong ability 
to stimulate cell proliferation and improve the energy metabolism of 
the skin was released by Pentapharm (Basel, Switzerland) [46]. New 
pilot plants are under development in India, Chile, Mexico, Cuba, Iran, 
Taiwan, Japan, Spain, and Kuwait [38].
ALGAL MACROMOLECULES AS BIOACTIVE COMPOUNDS AND 
THEIR PHYSIOLOGICAL EFFECTS
Oxidative damage caused by reactive oxygen species (ROS) to lipids, 
proteins, and nucleic acids can cause many chronic diseases such as 
heart disease, atherosclerosis, cancer, and aging. In general, microalgal 
strains are considered a rich source of antioxidants, with potential 
applications in pharmaceuticals, food, and cosmetics [47]. Antioxidant 
compounds, such as dimethylsulfoniopropionate and mycosporine 
amino acids, were isolated from microalgae and are potent chemical 
blockers of UV radiation [48]. In addition to these compounds, 
pigments, lipids, and polysaccharides with antioxidant activity can also 
be found in microalgae.
Good examples of such compounds are the C-PC is a blue photosynthetic 
pigment that belongs to the group of phycobiliproteins found in large 
quantities in the cyanobacteria, Rhodophyta, and Cryptophyte [49]. PC 
has applications as a nutrient and natural food colorants and cosmetics. 
In addition, it has application in medical diagnostics and pharmacology 
in the detection of cancer, and therefore, of great pharmaceutical 
importance. It is usually extracted from the biomass of Spirulina [50], 
Porphyridium cruentum [51] and Synechococcus [49]. Among the 
carotenoid compounds, β-carotene and astaxanthin are prominent. 
These compounds have application in the food and pharmaceutical 
industries because of their antioxidant properties and pigmentation 
ability.
Polysaccharides represent a class of high value-added components with 
applications in pharmaceuticals, food, cosmetics, fabrics, stabilizers 
and emulsifiers [52]. Microalgal polysaccharides contain sulfate esters, 
are referred to as sulfated polysaccharides, and possess unique medical 
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applications. The basic mechanism of therapeutic action is based on the 
stimulation of macrophages and modulation. The biological activity of 
sulfur polysaccharides is linked to their sugar composition, position, 
and degree of sulfation [53]. Some studies have reported that sulfated 
polysaccharides derived from microalgae inhibit viral infection, such as 
encephalomyocarditis virus, Herpes simplex virus types 1 and 2 (HSV1, 
HSV2), HIV, hemorrhagic septicemia in salmonid virus, swine fever 
virus, and varicella virus [54,55].
Carrageenan is a sulfated polysaccharide that can directly bind to 
human papillomavirus to inhibit not only the viral adsorption process 
but also the input and the subsequent process of the uncoating of the 
virus [56]. The importance of polysaccharides in the pharmaceutical 
industry lies in the fact that the extraction of this compound is relatively 
easy from microalgae.
The lipid compositions of microalgae are found to be responsible for 
its antimicrobial activity. This antimicrobial property of microalgae 
is because of their potential to produce compounds such as α- and 
β-ionone, β-cyclocitral, neophyte diene, and phytol 55. Antimicrobial 
activity against human pathogens, such as E. coli, Pseudomonas 
aeruginosa, S. aureus, and Staphylococcus epidermidis, has been 
attributed to γ-linolenic acid, eicosapentaenoic acid, hexadecatrienoic 
acid, docosahexaenoic acid, palmitoleic acid, lauric acid, oleic acid, 
lactic acid, and arachidonic acid [57].
Microalgae produce several anti-inflammatory compounds in their 
biomass that may exert a protective function in the body when 
consumed as food or used as pharmaceuticals and cosmetics. Because 
of their anti-inflammatory properties, microalgal biomass is being 
considered for applications in tissue engineering for the development 
of scaffolds, for use in the reconstitution of organs and tissues [58,59]. 
This is an important application for humans, especially in patients 
with burns in which the skin was completely lost [60]. Microalgal 
compounds with such properties are the long-chain PUFAs [61,62], 
sulfurized polysaccharides [63], and pigments [64]. Many microalgal 
polysaccharides possess the ability to modulate the immune system 
through the activation of macrophage functions and the induction of 
ROS, nitric oxide, and various other types of cytokines/chemokines [65]. 
Macrophages are able to regulate several innate responses and secrete 
cytokines and chemo-cytokines that serve as signals for immune and 
inflammatory molecular reactions [66]. Sulfated polysaccharides with 
anti-inflammatory activity can be applied in skin treatments inhibiting 
the migration and adhesion of polymorphonuclear leukocytes [63].
In humans, the oxidation reactions driven by ROS can lead to irreversible 
damage to cellular components, including lipids, proteins, and DNA 
degradation and/or mutation. Consequently, this damage can lead 
to several syndromes such as cardiovascular disease, some cancers, 
and the degenerative diseases of aging [67]. Pigments derived from 
microalgae have neuroprotective properties, being valuable sources as 
functional ingredients in pharmaceutical products that show efficient 
action in the treatment and/or prevention of neurodegenerative 
diseases. Vitamin E derived from algae has preventive effects for 
many diseases, such as atherosclerosis and heart disease, as well as 
neurodegenerative diseases, such as multiple sclerosis [68].
Carotenoids have great potential benefits to human health, including 
the treatment of degenerative diseases, such as macular degeneration 
and cataract development. These compounds act as antioxidants, 
reducing oxidative damage by ROS. Studies indicated that increased 
intake of phenols decreased the occurrence of degenerative diseases. 
Phenolic compounds from microalgae with the potential to fight free 
radicals have been reported [69].
Scientific findings indicate astaxanthin for multimodal intervention for 
many forms of degenerative diseases, including cardiovascular diseases, 
cancer, metabolic syndrome, cognitive impairment, age-related immune 
dysfunction, stomach and ocular diseases (macular degeneration, 
cataract, glaucoma, diabetic retinopathy, and retinitis pigmentosa), 
and skin damage [70]. High levels of lycopene from algae in plasma and 
tissues were inversely related to coronary heart disease, myocardial 
infarction, and the risk of atherosclerosis [70].
CONCLUSION
Bioactive metabolites of microalgal origin are of special interest in 
the development of new products for pharmaceutical, cosmetic, and 
food industries. Further research should be conducted with these 
bioactive compounds to verify their beneficial effects for humans, 
their degradability when released into the environment, and their 
effects when used in animals. Pharmaceutically valuable products and 
its industrial commercialization today are still in its infancy and can 
be seen as a gateway to a multibillion dollar industry. Scientists have 
just started to tap the enormous biological resource and physiological 
potential of microalgal species growing in all ecological niches. In 
recent years, innovative processes and products have been introduced 
in both macro- and microalgal biotechnology. One can expect that 
future trends in the involvement of microalgal utilization in the 
pharmaceutical industry will lead to a diversity of technical solutions 
for the use of PBR for cultivating microalgae. These will be adapted 
to the autecological demands of strains and to application aims for 
biomass, valuable substances, and ecology. An exhaustive inventory 
of species in all regions accompanied by proper taxonomic handling 
and strain collection could be a basis for future success. While the use 
of microalgae in functional foods and animal feed could soon reach 
the level of mass products, their use in pharmaceutical applications 
appears to be developing very rapidly.
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